Prognostic and Clinical Significance of Human Leukocyte Antigen Class I Expression in Breast Cancer: A Meta-Analysis

Qiao, Weiqiang; Jia, Zhiqiang; Guo, Wanying; Liu, Qipeng; Guo, Xingqi; Deng, Miao

doi:10.1007/s40291-023-00664-z

Cited by 4 publications

(2 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HLA class I expression in the cancer cells assessed by immunostaining is associated with prognosis in clinical samples from various malignancies. Representative studies showing the prognostic significance of HLA class I expression in tumors evaluated by immunohistochemistry using FFPE specimens are summarized in Table 1 49–51,55–114 . Many studies have concluded that the loss of HLA class I heavy chain expression is correlated with a worse prognosis, although some studies did not.…”

Section: Significance Of Evaluating Hla Class I Molecules Expressed I...unclassified

Assessment of cancer cell‐expressed HLA class I molecules and their immunopathological implications

Kubo,

Asano,

Sasaki

et al. 2024

HLA

View full text Add to dashboard Cite

Immunotherapy using immune checkpoint inhibitors (ICIs) has shown superior efficacy compared with conventional chemotherapy in certain cancer types, establishing immunotherapy as the fourth standard treatment alongside surgical intervention, chemotherapy, and radiotherapy. In cancer immunotherapy employing ICIs, CD8‐positive cytotoxic T lymphocytes are recognized as the primary effector cells. For effective clinical outcomes, it is essential that the targeted cancer cells express HLA class I molecules to present antigenic peptides derived from the tumor. However, cancer cells utilize various mechanisms to downregulate or lose HLA class I molecules from their surface, resulting in evasion from immune surveillance. Correlations between prognosis and the integrity of HLA class I molecules expressed by cancer cells have been consistently found across different types of cancer. This paper provides an overview of the regulatory mechanisms of HLA class I molecules and their role in cancer immunotherapy, with a particular emphasis on the significance of utilizing pathological tissues to evaluate HLA class I molecules expressed in cancer cells.

show abstract

Section: Significance Of Evaluating Hla Class I Molecules Expressed I...unclassified

Assessment of cancer cell‐expressed HLA class I molecules and their immunopathological implications

Kubo,

Asano,

Sasaki

et al. 2024

HLA

View full text Add to dashboard Cite

show abstract

“…Long-lasting antitumor immunity is mediated by coordinated activity of HLA-I and HLA-II-dependent pathways [19]. Loss of HLA function is associated with decreased antitumor defense and low therapeutic e cacy of immune checkpoint blockade [20,21]. Immune-mediated mechanisms of tumor development may have some relevance to BRCA1-driven neoplasms, as BRCA1 inactivation is accompanied by the de ciency in homologous DNA repair and, consequently, chromosomal instability.…”

Section: Introductionmentioning

confidence: 99%

HLA gene polymorphism is a modifier of age-related breast cancer penetrance in carriers of BRCA1 pathogenic alleles

Kuligina,

Romanko,

Jankevic

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose Female carriers of germline BRCA1 mutations almost invariably develop breast cancer (BC) however the age at onset is a subject of variation. We hypothesized that the age-related penetrance of BRCA1 mutations may depend on inherited variability in the host immune system. Methods Next-generation sequencing was utilized for genotyping of HLA class I/II genes (HLA-A, HLA-B, HLA-C, HLA-DPB1, HLA-DQB1 and HLA-DRB1/3/4/5) in patients with BRCA1-associated BC with early (</= 38 years, n = 215) and late (>/= 58 years, n = 108) age at onset. Results HLA-DQB1*06:03P prevalence was higher in the late-onset group due to the excess of allele carriers [25/108 (23.1%) vs. 22/215 (10.2%); OR 2.96, p < 0.001]. For all HLA-I loci, there was a trend towards an increase in the number of homozygotes in the early-onset group. This trend reached statistical significance for the HLA-A [14.4% vs. 6.5%, p = 0.037; OR 2.4, p = 0.042]. The frequencies of HLA-DPB1, HLA-DQB1 and HLA-DRB1/3/4/5 homozygous genotypes did not differ between young-onset and late-onset patients. The maximum degree of homozygosity detected in this study was 6 out of 7 HLA class I/II loci; all six carriers of these genotypes were diagnosed with BC at the age </= 38 years [OR = 6.97, p = 0.187]. Conclusion HLA polymorphism may play a role in modifying the penetrance of BRCA1 pathogenic variants. Certain HLA alleles or HLA homozygosity may modify the risk of BC in BRCA1 carriers.

show abstract

HLA gene polymorphism is a modifier of age-related breast cancer penetrance in carriers of BRCA1 pathogenic alleles

Kuligina,

Romanko,

Jankevic

et al. 2024

Breast Cancer Res Treat

View full text Add to dashboard Cite

Prognostic and Clinical Significance of Human Leukocyte Antigen Class I Expression in Breast Cancer: A Meta-Analysis

Cited by 4 publications

References 58 publications

Assessment of cancer cell‐expressed HLA class I molecules and their immunopathological implications

Assessment of cancer cell‐expressed HLA class I molecules and their immunopathological implications

HLA gene polymorphism is a modifier of age-related breast cancer penetrance in carriers of BRCA1 pathogenic alleles

HLA gene polymorphism is a modifier of age-related breast cancer penetrance in carriers of BRCA1 pathogenic alleles

Contact Info

Product

Resources

About